MetF has also been shown to restore the sensitivity of human CRC cell lines for TRAIL in vitro via degradation of antiapoptotic Mcl-1 protein, a member of the Bcl-2 family [30] and turned out to be very promising also in combination with immunotherapy with check-point inhibitors [89,90]. The gene discussed is MCL1; the disease is colorectal carcinoma.